BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sosei Group Corporation Assigns AD 923 Assets to Pharmasol


10/6/2009 7:48:32 AM

TOKYO, October 6 /PRNewswire-FirstCall/ -- Sosei Group Corporation , the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd. ("Pharmasol"), a privately held UK company.

The AD 923 development programme had previously entered Phase III clinical trials in Europe. However, due to the changes in regulatory environment, restructuring of Sosei R&D business operation, the programme had been halted.

Based on the present agreement Sosei R&D will receive payments from Pharmasol based on revenues arising from the commercialization of these assigned assets.

Editor's notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Pharmasol

Pharmasol Corporation engages in the contract manufacturing, packaging, and warehousing of aerosols, liquids, gels, and lotions for the health care and cosmetics industries. It also offers consultancy services, including research and development, purchasing, and marketing.

For further information about Pharmasol, please visit http://www.pharmasol.co.uk

SOURCE Sosei Group Corporation

CONTACT: Enquiries: Sosei Group Corporation: Kojimachi Tsuruya Hachiman
Bldg. 5F, 2-4 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Japan, Hidetoshi
Torami, E-mail: htorami@sosei.com, Tel: +81-3-5210-3399, Fax:
+81-3-5210-3291; Sosei R&D Ltd: 1F London BioScience Innovation Centre, 2
Royal College Street, London NW1 0NH, Dr Michael Murray, Managing Director,
E-mail: mmurray@sosei.com, Tel: +44-20-7691-2081, Fax: +44-20-7209-2484



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES